DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Thrombelastogram in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery

Information source: Sheba Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bleeding

Phase: N/A

Status: Recruiting

Sponsored by: Sheba Medical Center

Official(s) and/or principal investigator(s):
Sergey Preisman, MD, Principal Investigator, Affiliation: Sheba Medical Center
Alexander Kogan, MD, Study Director, Affiliation: Sheba Medical Center

Summary

Study Objective is to correlate the results of preoperative platelet mapping derived from modified TEG with clinically significant postoperative bleeding and consumption of blood products.

Clinical Details

Official title: Thrombelastogram and Predicting Microvascular Bleeding in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Re-sternotomy d/t Bleeding

Secondary outcome: Chest tube output during first 24 hours after the surgery

Detailed description: Study Design: Prospective observational study with blinded assessment of study endpoint variables. Collection of information concerning study endpoints will be performed by the investigator blinded to the results of preoperative testing of platelet function. The information will be collected from 60 patients undergoing cardiac surgery in the Department of Cardiac Surgery of Sheba Medical Center. Study endpoints 1. Primary endpoint- resternotomy for bleeding after the surgery. 2. Secondary endpoints- chest tube output during first 24 hours after the surgery; consumption of blood products during first 3 postoperative days.

Eligibility

Minimum age: 18 Years. Maximum age: 90 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients undergoing cardiac surgery with the history of aspirin and/or ADP receptor

antagonist for at least 7 days prior the surgery Exclusion Criteria:

- Emergent surgery

- Heart transplant surgery

- Implantation of ventricular assist devices

- Enrollment into conflicting study

Locations and Contacts

Sheba Medical Center, Tel Hashomer 52621, Israel; Recruiting
Sergey Preisman, MD, Phone: 052-6667205, Email: sergey.preisman@sheba.health.gov.il
Sergey Preisman, MD, Principal Investigator
Additional Information

Starting date: May 2008
Last updated: October 22, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017